An in silico disease model for the development of FXR agonist EYP001 as a therapy for HBV infection.

poster

(2019), AASLD - The Liver Meeting, Boston (USA)

Claudio Monteiro, Lara Bruezière, Samuel Laheux, Marc Hommel, Pauline Radreau, Elise Roy, Raphaël Darteil, Patrice André, Jean-Pierre Boissel, Jacky Vonderscher and Pietro Scalfaro.

A regulatory landscape shift for in silico clinical trials

publi

(2019) Regulatory Rapporteur, vol. 16, no. 11, pp. 18-21

Cécile F Rousseau, Cécile Crozatier, David A duVerle, Marc Buyse, Susan E Carter, Emmanuelle M Voisin, François-Henri Boissel

From Clinical Trial Efficacy to Real-Life Effectiveness: Why Conventional Metrics do not Work.

publi

(2019) Drugs-real world outcomes, vol. 6, no. 3, pp. 125-132

Jean-Pierre Boissel, Frédéric Cogny, Marko Nicholas, François-Henri Boissel.

In silico exploration of immunotherapeutics combinations in lymphoma

poster

(2018), ICSB, Lyon (France)

Lara Brueziere, Adèle L’Hostis, Eulalie Landèche, Emmanuelle Bechet, Polina Kurbatova, Loïc Etheve, Jean-Pierre Boissel.

A logical modelling approach to prepare and accelerate the design of ODE models: Application to bile acid metabolism

poster

(2018), ICSB, Lyon (France)

Lara Brueziere, Eliott Tixier, Elise Roy, Arnaud Poret, Claudio Monteiro, Pietro Scalfaro, Jean-Pierre Boissel.

An in silico HBV model predicts viral response to the oral non-steroidal carboxylic acid FXR agonist EYP001a.

poster

(2018), PAGE meeting, Montreux (Switzerland)

Claudio Monteiro, Evgueni Jacob, Bastien Martin, Samuel Laheux, Diane Sampson, Elise Roy, Jacky Vonderscher, Pietro Scalfaro, Patrice André, Jean-Pierre Boissel.

Comparative transcriptomic analysis between an artificially induced SIRS in healthy individuals and spontaneous sepsis

publi

(2015) Comptes Rendus Biologies, vol. 338, no. 10, pp. 635-642

Claudio Monteiro, Jean-Pierre Boissel, François Gueyffier, Gustavo Olivera-Botello

Bridging Systems Medicine and Patient Needs

publi

(2015) CPT: Pharmacometrics & Systems Pharmacology, vol. 4, no. 3, pp. 135-145

J-P Boissel, C Auffray, D Noble, L Hood, F-H Boissel

Comparison of an effect-model-law-based method versus traditional clinical practice guidelines for optimal treatment decision-making: application to statin treatment in the French population

publi

(2014) Journal of The Royal Society Interface , vol. 11, no. 100, pp. 20140867-20140867

R. Kahoul, F. Gueyffier, E. Amsallem, M. Haugh, I. Marchant, F.-H. Boissel, J.-P. Boissel

Prediction of chronic lung allograft dysfunction: a systems medicine challenge

publi

(2014) European Respiratory Journal, vol. 43, no. 3, pp. 689-693

C. Pison, A. Magnan, K. Botturi, M. Seve, S. Brouard, B. J. Marsland, F. Ernst, T. Paprotka, K. Deplanche, A. Fritz, V. Siroux, J.-P. Boissel, P. A. Corris, C. Auffray, L. P. Nicod, on behalf of the SysCLAD consortium

Effect Model Law: An Approach for the Implementation of Personalized Medicine

publi

(2013) Journal of Personalized Medicine , vol. 3, no. 3, pp. 177-190

Jean-Pierre Boissel, Riad Kahoul, Draltan Marin, François-Henri Boissel

Towards personalized medicine: exploring the consequences of the effect model-based approach

publi

(2011) Personalized Medicine, vol. 8, no. 5, pp. 581-586

Jean-Pierre Boissel, Riad Kahoul, Emmanuel Amsallem, François Gueyffier, Margaret Haugh, François-Henri Boissel